An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

NCT02577406 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

319

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid
Isocitrate Dehydrogenase

Interventions

DRUG: AG-221
OTHER: BSC
DRUG: Azacitidine
DRUG: Low-dose cytarabine (LDAC)
DRUG: Intermediate-dose cytarabine (IDAC)

Sponsor

Celgene